TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targetsDavid T Yeung, Timothy P. Hughes, Deborah L. White et al.|Blood|2014Cited by 102
Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter studyJorge J. Castillo, Steven P. Treon, Alessandra Tedeschi et al.|Blood|2018Cited by 100